Notícias e Atualizações de Maat

MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology

Tranche-based financing to support clinical development for the Company’s late-stage assets in hem...

Jul 27, 2025 • Yahoo Finance

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe

In June 2025, the European Medicines Agency accepted for review the marketing authorization submissi...

Jul 01, 2025 • Yahoo Finance

MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan

MaaT Pharma secures important funding in line with one of the goals under the Health Innovation 2030...

Nov 30, 2023 • Business Wire

MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

LYON, France--(BUSINESS WIRE)--Regulatory These encouraging findings from the IASO Phase 1b trial c...

May 11, 2025 • Business Wire

MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026

In May 2026, the Company was informed of a “negative trend” opinion on its Marketing Authorizati...

May 26, 2026 • PharmiWeb

MaaT Pharma to Hold Annual General Meeting on June 16, 2026

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a lea...

May 11, 2026 • Morningstar

Maat (Atenolol) Drug Price and Information

atenolol (Maat) (Maat) blocks beta-1 receptors, which are present on the heart. This prevents the ac...

Aug 07, 2019 • Medindia

Maat Pharma SA MAAT

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies...

Jun 02, 2026 • Morningstar

MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress

LYON, France--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the “Company”), a cli...

May 14, 2025 • Business Wire

Is MaaT back? After 18 months on hold, microbiome biotech sees end to impasse with FDA

MaaT Pharma’s 18-month struggle to get out from under an FDA clinical hold may be entering its end...

Feb 03, 2023 • FierceBiotech

MaaT, eyeing 2026 launch for microbiome therapy, posts 18-month data in aGvHD

A year after a long-running clinical hold was lifted on MaaT Pharma’s pooled fecal therapy, the mi...

Apr 15, 2024 • FierceBiotech

MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a lea...

Mar 09, 2026 • Business Wire

MaaT microbiota drug shows survival advantage in GvHD

MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with ne...

Apr 16, 2024 • pharmaphorum

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

LYON, France--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the “Company”), a cli...

Jan 21, 2025 • Business Wire

AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for Ma...

Apr 28, 2025 • pharmaphorum

Availability of MaaT Pharma’s 2024 Universal Registration Document (URD)

LYON, France--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the “Company”), a cli...

May 20, 2026 • Business Wire